Navinci is pleased to highlight the publication of a new study in Nature Communications reporting findings from the ASTEROID Phase 1 clinical trial.
Navinci announces the launch of NaveniBright™ AUTO, extending its automated isPLA portfolio to open automated staining platforms.
Navinci highlights a new preprint by Associate Professor Charlotte Stadler and collaborators, using in situ PLA to detect PD-1/PD-L1 interactions linked to immunotherapy response.
Navinci today announces that the company has initiated a collaboration with BrainZell to explore the use of Navinci’s in situ Proximity Ligation Assay technology in human brain organoid models to support relevant studies of biology and drug response.
Navinci is pleased to announce the recipients of the 2026 Spatial Interactomics Grant.
Navinci and Lumito initiate pilot project – promising initial results from evaluation of combined technology
Navinci is pleased to announce that Dr. Di Peng has been awarded a DDLS Postdoctoral Fellowship 2026, with Navinci as the industrial host
Navinci announces its participation in the European Association for Cancer Research (EACR) 2026 Congress, taking place from June 8–11, 2026 in Budapest, Hungary.
Navinci announces Omni is a multiplex in situ proximity ligation assay with a fluorescent readout, enabling the simultaneous detection of up to 9 protein–protein interactions, post-translational modifications, or single protein targets with high specificity and sensitivity.
Navinci to attend AACR and continue the pre-launch of new multiplex kit
Navinci enters into cross-institutional collaboration for high-throughput spatial interactomics
Navinci to attend NextGen Omics and Spatial Biology US as silver sponsor and pre-launch new multiplex kit